UNASSIGNED: Background and study aims: Discontinuation of all antiplatelet agents before endoscopic procedures may cause serious complications in some @entity1 . The aim of this study was to evaluate the hemorrhagic risk of @entity5848 ( @entity5848 ) in patients on antiplatelet therapy (APT). @entity1 and methods: The subjects were 350 @entity1 (377 lesions) who underwent gastric @entity5848 between January 2007 and July 2013. The @entity1 were categorized based on antiplatelet therapies. The primary outcome was post- @entity5848 @entity548 . Multivariate analysis was performed to identify independent risk factors for post- @entity5848 @entity548 . Results: The @entity1 were categorized into three groups: (1) no APT, 261 @entity1 with 281 lesions; (2) single APT, 58 @entity1 with 63 lesions (53 @entity1 with low dose @entity117 [LDA] and 5 @entity1 with a @entity1747 ); and (3) dual APT (DAPT), 31 @entity1 with 33 lesions (DAPT with LDA and a @entity1747 ). Post- @entity5848 @entity548 occurred in 16 of 261 @entity1 in the no APT group (6.1%), 9 of 58 @entity1 in the single APT group (15.5%), and 11 of 31 @entity1 in the DAPT group (35.5%). In multivariate analysis with a Cox proportional hazards model in the no APT and single APT groups, APT (HR 2.7, 95%CI 1.1-6.6, P=0.03) and diameter of the resected specimen of 40mm or greater (HR 2.7, 95%CI 1.2-5.9, P=0.01) were significant risk factors for post- @entity5848 @entity548 . In multivariate analysis in the no APT and DAPT groups, DAPT was the only significant risk factor for post- @entity5848 @entity548 (HR 16.3, 95%CI 3.4-78.2, P<0.01). Continuous LDA was not a significant risk factor for post- @entity5848 @entity548 in both analyses (HR 0.8, 95%CI 0.2-3.6, P=0.72 in the no APT and single APT groups; HR 1.0, 95%CI 0.2-5.1, P=0.95 in the no APT and DAPT groups). Conclusions: APT increased the risk for post- @entity5848 @entity548 , and DAPT markedly increased the risk for @entity548 . Continuous LDA did not produce an additional hemorrhagic risk in all @entity1 treated with APT. Thus, @entity1 treated with APT should be careful monitored for post- @entity5848 @entity548 , and LDA should not be interrupted in @entity1 with a high @entity1031 risk.

Continuous @entity117 use does not increase post-endoscopic dissection XXXX risk for gastric neoplasms in patients on antiplatelet therapy.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity1747 :: ('MESH:C446540', 'Chemical') :: ['thienopyridine'] @entity5848 :: ('MESH:D000784', 'Disease') :: ['ESD', 'post-endoscopic submucosal dissection'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic']
@entity548 :: (MESH:D006470,Disease) :: ['bleeding']
